血液灌流联合连续性静脉-静脉血液滤过治疗急性百草枯中毒的Meta分析
该Meta分析纳入21项研究共2222例16岁以上急性百草枯中毒患者,比较血液灌流联合连续性静脉-静脉血液滤过(实验组976例)与单用血液灌流(对照组1246例)的临床疗效。结果显示联合组死亡率43.77%(362/827)显著低于对照组55.26%(604/1093),OR=0.68(95%CI 0.56-0.82,P=0.0001);死亡患者生存时间显著延长(MD=4.63,95%CI 2.60-6.66,P<0.00001);多器官功能障碍综合征发生率25.93%(70/270)vs 55.36%(155/280),OR=0.26(95%CI 0.14-0.49);急性呼吸窘迫综合征发生率30.37%(82/270)vs 51.07%(143/280),OR=0.42(95%CI 0.30-0.61);无效率8.72%(13/149)vs 34.64%(53/153),OR=0.17(95%CI 0.09-0.34)。漏斗图显示除死亡率外其他指标发表偏倚较小。
要点
- 纳入21项研究2222例16岁以上急性百草枯中毒患者,联合组976例、单用血液灌流组1246例。
- 联合组死亡率43.77%(362/827) vs 单用组55.26%(604/1093),OR=0.68(95%CI 0.56-0.82,P=0.0001)。
- 联合组死亡患者生存时间较单用组延长,MD=4.63(95%CI 2.60-6.66,P<0.00001)。
- 联合组多器官功能障碍综合征发生率25.93%(70/270) vs 55.36%(155/280),OR=0.26(95%CI 0.14-0.49)。
- 联合组急性呼吸窘迫综合征发生率30.37%(82/270) vs 51.07%(143/280),OR=0.42(95%CI 0.30-0.61);无效率8.72%(13/149) vs 34.64%(53/153),OR=0.17(95%CI 0.09-0.34)。
适用人群与场景
- 16岁以上的急性百草枯中毒患者,纳入中文和英文的随机对照试验、病例对照研究和队列研究。
研究设计与关键结果
- Meta分析纳入21项研究共2222例受试者,其中血液灌流联合连续性静脉-静脉血液滤过组(实验组)976例,单用血液灌流组(对照组)1246例。
- 与对照组相比,实验组死亡率显著降低:43.77%(362/827) vs 55.26%(604/1093),OR=0.68(95%CI 0.56-0.82,P=0.0001)。
- 实验组死亡患者生存时间较对照组显著延长:MD=4.63(95%CI 2.60-6.66,P<0.00001)。
- 实验组多器官功能障碍综合征发生率显著低于对照组:25.93%(70/270) vs 55.36%(155/280),OR=0.26(95%CI 0.14-0.49,P<0.0001)。
- 实验组急性呼吸窘迫综合征发生率显著低于对照组:30.37%(82/270) vs 51.07%(143/280),OR=0.42(95%CI 0.30-0.61,P<0.00001)。
- 实验组无效率显著低于对照组:8.72%(13/149) vs 34.64%(53/153),OR=0.17(95%CI 0.09-0.34,P<0.00001)。
- 漏斗图显示,除死亡率存在发表偏倚外,其他指标的发表偏倚较小。
证据类型、等级与局限
- 证据类型:Meta分析,纳入随机对照试验、病例对照研究和队列研究。
- 局限:死亡率指标存在发表偏倚。
对床旁实践的改变
- 作者认为,与单用血液灌流相比,血液灌流联合连续性静脉-静脉血液滤过总体上可显著降低急性百草枯中毒患者死亡率、延长生存时间、减少多器官功能障碍综合征和急性呼吸窘迫综合征的发生,从而提高治疗有效率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To comprehensively evaluate the clinical efficacy of hemoperfusion (HP) combined with continuous veno-venous hemofiltration (CVVH) on acute paraquat poisoning (APP).
METHODS: Literatures of Chinese and English randomized controlled trials (RCTs), case control and cohort study on HP combined with CVVH in the treatment of APP from the PubMed, Embase, Wanfang, and CNKI up to November 2017 were enrolled (the subjects were > 16 years old). The obtained literatures were strictly screened and evaluated in quality, and data such as mortality, the life time of dead patients, inefficiency rate, incidence of multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS) were extracted. Meta-analysis was performed by RevMan 5.3.
RESULTS: Twenty-one studies were included with 2 222 subjects, among whom 976 subjects were in HP combined with CVVH group (experimental group) and 1 246 subjects in HP group (control group). Compared with control group, the mortality in experimental group were significantly decreased [43.77% (362/827) vs. 55.26% (604/1 093), odds ratio (OR) = 0.68, 95% confidential interval (95%CI) = 0.56-0.82, P = 0.000 1], the life time of death patients was significantly prolonged [mean difference (MD) = 4.63, 95%CI = 2.60-6.66, P < 0.000 01], incidence of MODS [25.93% (70/270) vs. 55.36% (155/280), OR = 0.26, 95%CI = 0.14-0.49, P < 0.000 1], and incidence of ARDS [30.37% (82/270) vs. 51.07% (143/280), OR = 0.42, 95%CI = 0.30-0.61, P < 0.000 01], and inefficiency rate [8.72% (13/149) vs. 34.64% (53/153), OR = 0.17, 95%CI = 0.09-0.34, P < 0.000 01] were significantly reduced. Funnel chart showed that except the publication bias of mortality rate, there were less publication bias about other indicators among studies.
CONCLUSIONS: HP combined with CVVH can significantly reduce the mortality of patients with APP compared with HP alone on the whole, prolong the life time and reduce the occurrence of MODS and ARDS, thus improving the treatment efficiency.
参考来源
- Lan C, Lyu Q, Pei H, et al. [Effect of hemoperfusion combined with continuous veno-venous hemofiltration on acute paraquat poisoning: a Meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 30220282. doi:10.3760/cma.j.issn.2095-4352.2018.08.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。